Latest Share Chat

SUMM.L Share News (SUMM)

SUMM.L Information

There is currently no data for SUMM

Summit Therapeutics surges on positive clinical trial update

Mon, 17th Aug 2015 12:33

(ShareCast News) - Shares in Summit Therapeutics surged after the company said that its phase 1B clinical trial of SMT C1100 for the treatment of Duchenne muscular dystrophy met its primary objective and will now move on to a Phase 2 trial.The drug discovery and development company said half of the patients who received the higher dose of SMT C1100 achieved the desired plasma levels while following specific dietary guidance.Initial analysis showed six of 12 patients achieved the desired plasma level after receiving a 2,500 mg dose of SMT C1100 twice daily for 14 days. In a prior Phase 1b trial, only two of 12 patients dosed with SMT C1100 achieved the desired plasma level.Summit said SMT C1100 was well tolerated at all doses tested with no serious adverse events reported.The company said it plans to start the Phase 2 open-label trial in the fourth quarter of this year to evaluate the longer-term benefits of the drug on muscle health, function and safety.Summit's chief executive officer, Glyn Edwards, said: "These data clear an important hurdle in the development of SMT C1100 by demonstrating it is a viable drug candidate to bring proof-of-concept for the Company's burgeoning utrophin modulator pipeline and more importantly, hope to all patients and their families living with this devastating disease."Our priority is advancing SMT C1100 efficiently through future patient clinical trials designed to evaluate the potential clinical benefit of this promising treatment, and this will start with an open-label Phase 2 trial that is expected to start by the end of this year."At 1247 BST, Summit shares were up 9.6% at 172.60p.

More News

27 Mar 2019 15:56

Summit Therapeutics Swings To Annual Profit On Sarepta Agreement

LONDON (Alliance News) - Summit Therapeutics PLC on Wednesday said it swung to a profit in its most recent financial year due to the recognition of revenue from its Sarepta Therapeutics Inc pretax

2 Jan 2019 14:08

Polar Capital Holds 6% Summit Therapeutics Stake After Deal (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Wednesday that Polar Capital LLP holds a 6.47% stake in the drug developer after a transaction on December 21.Polar Capital's the

17 Dec 2018 09:14

Summit Therapeutics proposes $25m fundraiser

(Sharecast News) - Antibiotics developer Summit Therapeutics has entered into a securities purchase agreement for the sale of $25m worth of its US-listed shares in order to extend its cash runway through to January 2020.

11 Dec 2018 16:34

Summit Therapeutics' loss expands on one-off charges

(Sharecast News) - Summit Therapeutics on Tuesday reported that its third quarter loss expanded due to one-off charges, but stated that the company has swung to a profit over the first nine months of the year.

11 Dec 2018 14:31

Summit Therapeutics Third-Quarter Loss Widens Due To One-Off Charges

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday its third-quarter loss widened sharply due to one-off charges.For the three months ended October 31, the company reported loss

6 Sep 2018 13:55

Summit Therapeutics Discovers New Antibiotics For Superbug Infections

LONDON (Alliance News) - Clinical stage drug company Summit Therapeutics PLC on Thursday said it has discovered multiple new mechanism antibiotics to treat "superbug" antibiotics are at

16 Aug 2018 13:53

Summit Therapeutics Shares Jump As Secures Extra USD12 Million Funding

LONDON (Alliance News) - Summit Therapeutics PLC on Thursday said it secured additional USD12 million from Biomedical Advanced Research & Development Authority, a division of the US Department

20 Apr 2018 13:11

Summit Therapeutics Gets Encouraging Results From Ezutromid Trials

LONDON (Alliance News) - Summit Therapeutics PLC on Friday said new work showed a correlation between a reduction in a muscle damage biomarker and the use of its proposed treatment said analysis a

19 Apr 2018 15:07

Summit Therapeutics Completes Dosing For PhaseOut Clinical Trial

LONDON (Alliance News) - Summit Therapeutics PLC said on Thursday it has completed the ezutromid dosing of patients with Duchenne muscular dystrophy for the full 48-week PhaseOut DMD clinical was

4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

27 Mar 2018 12:18

Summit Therapeutics To Raise GBP15 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday that it intends to raise gross proceeds of up to GBP15.0 million via share placing.The to a

14 Mar 2018 17:52

Summit Therapeutics Reports Progress On PhaseOut DMD Trial

LONDON (Alliance News) - Summit Therapeutics PLC at the clinical conference in Arlington highlighted the rigour in the data collection in analysis for its PhaseOut Duchenne 2

1 Feb 2017 16:50

Summit Therapeutics outlines next stage of ridinilazole development

(ShareCast News) - Drug discovery and development company Summit Therapeutics outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory meetings with the US Food and Drug Administration and European Medicines Agency. The AIM-traded firm said, with input from

1 Feb 2017 12:15

Summit Therapeutics Details Phase III Programme For Ridinilazole

18 Jan 2017 12:09

Latest Share Chat

SUMM.L Share News (SUMM)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Summit Therapeutics surges on positive clinical trial update

Login to your account

Quickpicks are a member only feature

Login to your account